The latest research found the imbalance of functional B cell subsets has been implicated in the pathogenesis of MS, with targeted inhibition of B-cell receptor (BCR) signaling pathways, mitochondrial respiration, or adenosine triphosphate (ATP) receptors showing potential therapeutic benefits (13). This evidence concerns the gene BCR and myeloid sarcoma.